CorMedix (CRMD) Investor Day 2026 summary

Strategic transformation and portfolio evolution

• Transitioned from a single-product, renal-focused company to a diversified specialty pharmaceutical platform with multiple commercial-stage drugs and a robust pipeline, following the Melinta acquisition and integration of new leadership roles.

• Completed acquisition of Melinta Therapeutics, expanding the portfolio with synergistic acute care assets and driving 2025 pro forma revenue above $400 million.

• Focused on organic growth, new indications, and leveraging a dynamic institutional platform for future expansion.

• Positioned for continued value creation through strategic business development and financial flexibility.

• Announced a $75 million share repurchase program, reflecting confidence in undervalued shares and strong cash flow.

Financial guidance and performance

• FY 2025 pro forma net revenue exceeded $400 million, with DefenCath contributing ~$260 million during its peak TDAPA period and Melinta's $140 million contribution.

• FY 2026 revenue guidance is $300–320 million, with adjusted EBITDA expected at $100–125 million and a market cap approximately five times EBITDA guidance.

• FY 2026 DefenCath sales projected at $100–140 million, rebounding in 2027 with increased add-on payments and demand as CMS adds more dollars to the dialysis bundle.

• Cash and short-term investments at year-end 2025 totaled $148 million, with $150 million in convertible debt.

Portfolio and pipeline developments

• Expanded commercial portfolio post-Melinta, focusing on injectable anti-infectives for institutional care settings, with synergy-driven business development.

• REZZAYO (rezafungin) launched in 2023 for candidemia/invasive candidiasis, targeting a $250–350 million market, with ongoing phase III and II studies for prophylaxis and additional indications.

• DefenCath is being advanced in a phase III study for prevention of CLABSI in TPN patients, targeting a $500–$750 million addressable market.

• Multiple late-stage and preclinical programs in pipeline, including expansion into prophylaxis and pediatric hemodialysis.

• Strategic investment in Talphera provides a toehold in acute care, with near-term data readout expected.